Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Mar 21, 2025; 31(11): 100911
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.100911
Table 1 Baseline characteristics of patients in training group, n (%)
Variables
Total (n = 287)
Textbook outcome (n = 150)
None-textbook outcome (n = 137)
P value
Age, M (Q1, Q3)56.00 (48.00, 63.00)55.00 (47.00, 62.00)59.00 (49.00, 63.00)0.118
Sex0.011
    Male189 (65.85)109 (72.67)80 (58.39)
    Female98 (34.15)41 (27.33)57 (41.61)
Hepatitis B0.002
    Negative179 (62.37)81 (54.00)98 (71.53)
    Positive108 (37.63)69 (46.00)39 (28.47)
ECOG score0.026
    085 (29.62)53 (35.33)32 (23.36)
    1202 (70.38)97 (64.67)105 (76.64)
Child Pugh0.005
    A175 (60.98)80 (53.33)95 (69.34)
    B112 (39.02)70 (46.67)42 (30.66)
Tumor size, M (Q1, Q3)6.40 (4.65, 8.90)6.10 (4.30, 8.40)7.00 (5.00, 9.20)0.098
Tumor number0.870
    Solitary192 (66.90)101 (67.33)91 (66.42)
    Multiple95 (33.10)49 (32.67)46 (33.58)
TBIL, M (Q1, Q3)20.00 (12.95, 31.90)22.90 (14.50, 32.90)17.10 (11.20, 28.10)0.013
DBIL, M (Q1, Q3)7.90 (4.60, 14.75)8.85 (5.30, 15.45)7.30 (3.50, 14.40)0.012
CA19-9, M (Q1, Q3)17.30 (8.95, 34.20)20.90 (13.90, 33.55)11.50 (3.90, 37.30)< 0.001
AFP, M (Q1, Q3)12.70 (3.30, 171.50)29.10 (3.62, 314.50)7.40 (3.20, 78.20)0.065
CEA, M (Q1, Q3)2.60 (1.60, 4.10)2.45 (1.50, 4.00)2.60 (1.60, 4.60)0.219
Blood transfusion< 0.001
    No247 (86.06)150 (100.00)97 (70.80)
    Yes40 (13.94)0 (0.00)40 (29.20)
Surgical margins< 0.001
    Negative276 (96.17)150 (100.00)126 (91.97)
    Positive11 (3.83)0 (0.00)11 (8.03)
Complications< 0.001
    No227 (79.09)150 (100.00)77 (56.20)
    Yes60 (20.91)0 (0.00)60 (43.80)
Perioperative death or readmission within 30 days after discharge0.008
    No279 (97.21)150 (100.00)129 (94.16)
    Yes8 (2.79)0 (0.00)8 (5.84)
Prolonged hospitalization< 0.001
    No187 (65.16)150 (100.00)37 (27.01)
    Yes100 (34.84)0 (0.00)100 (72.99)